Irish Vaccination Awareness

Share with your friends!

GARDASIL®
RISK INFORMATION

AT THE TIME OF VACCINATION THE HSE DOES NOT PROVIDE THE PATIENT INFORMATION LEAFLET (PIL) TO PARENTS, WHICH SAYS TO TELL YOUR HEALTHCARE PROVIDER IF YOU EXPERIENCE ANY OF THE FOLLOWING KNOWN SIDE EFFECTS:

BREATHING DIFFICULTIES, SEIZURES, UNUSUAL TIREDNESS, WEAKNESS, CONFUSION (GUILLAINE BARRÉ SYNDROME), CHEST PAINS, SWOLLEN GLANDS, JOINT PAIN, LEG PAIN, FAINTING EPISODES, MUSCLE WEAKNESS, VOMITING, GENERALLY FEELING UNWELL, BLEEDING OR BRUISING MORE EASILY, STOMACH ACHE OR BOWEL PROBLEMS, HIVES, RASH, CHILLS, AND SKIN INFECTION AT THE INJECTION SITE.

A SUPPORT GROUP EXISTS FOR GIRLS INJURED BY THE HPV VACCINE: *WWW.REGRET.IE*

FOR TESTIMONIALS FROM GIRLS INJURED WORLDWIDE GO TO: *SANEVAX.ORG*

DOWNLOAD THE PATIENT INFORMATION LEAFLET AT: HTTPS://WWW.MERCK.COM/PRODUCT/USA/PI_CIRCULARS/G/GARDASIL/GARDASIL_PPI.PDF

THE PIL CONTAINS FURTHER INFORMATION ON SIDE EFFECTS AND CONTRAINDICATIONS, FOR E.G. ALLERGIES TO INGREDIENTS. REACTIONS CAN OCCUR UP TO SEVERAL MONTHS AFTER RECEIVING THE VACCINE. PLEASE TALK TO YOUR HEALTHCARE PROVIDER ABOUT ALL RISKS PER THE PIL BEFORE VACCINATING.

ADDITIONAL INFORMATION:

- CONTRARY TO CLAIMS MADE BY THE HSE GARDASIL HAS NOT BEEN PROVEN TO PREVENT CANCER.
- THE HSE CLAIMS THAT GARDASIL IS "VERY SAFE" HOWEVER, CLINICAL TRIALS SHOW A SERIOUS ADVERSE REACTION* RATE OF 2.5% (SEE THE PIL).
- THERE HAVE BEEN **861** REPORTED ADVERSE EVENTS IN IRELAND FROM SEPT 2010 TO MARCH 2015.
- THE VACCINE IS EXPECTED TO WANE AFTER 8 YEARS**, INFORMATION WHICH THE HSE HAS NOT SHARED WITH THE PUBLIC.
- INDEPENDENT TESTING REVEALED GARDASIL CONTAINS GENETICALLY ENGINEERED NON-HUMAN RECOMBINANT DNA (A BIOHAZARDOUS MATERIAL)***
- THERE IS NO VACCINE COMPENSATION SCHEME IN IRELAND TO COMPENSATE THOSE INJURED OR DISABLED BY VACCINE INJURY.
- THE HSE DOES NOT OFFER PRE-SCREENING FOR ALLERGIES TO THE INGREDIENTS IN THE VACCINE SO IT IS IMPOSSIBLE TO DETERMINE YOUR RISK OF HAVING AN ADVERSE REACTION.

*According to the FDA a serious adverse reaction event must fit one of the following criteria: death, life-threatening, hospitalization, disability or permanent damage, congenital abnormality/birth defect, or the requirement to intervene to prevent permanent impairment.
** "The monovalent experimental HPV 16 Gardasil precursor vaccine even showed a loss of 14% of measurable antibodies to HPV 16 after 8.5 years, supporting the belief that Gardasil boosters will be necessary before the 15 year threshold for actual cancer prevention". Prof. Diane Harper, Lead Researcher working on original Gardasil Clinical Trials: http://www.discoverymedicine.com/Diane-M-Harper/2010/07/03/prophylactic-hpv-vaccines-current-knowledge-of-impact-on-gynecologic-premalignancies/
*** http://sanevax.org/gardasil-contaminant-confirmed-independent-lab/